One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study

Table 1

Baseline characteristics and ranibizumab treatment.

	ITT population; (𝑛=471)	On-treatment population; (𝑛=370)
Baseline age (years)
Mean±SD	78.1±8.0	77.7±8.0
Range	46–93	46–93
Gender, 𝑛 (%)
Male	160 (34.0%)	123 (33.2%)
Female	311 (66.0%)	247 (66.8%)
Indication for ranibizumab, 𝑛 (%)
Wet AMD	468 (99.4%)	368 (99.5%)
Other	3 (0.6%)	2 (0.5%)
Baseline OCT performed, 𝑛 (%)
Yes	357 (75%)	242 (75%)
No	115 (24%)	82 (25%)
Unknown	2 (0.4%)	0
Baseline ETDRS, 𝑛 (%)
Yes	337 (71%)	223 (69%)
No	136 (28.6%)	101 (31%)
Unknown	2 (0.4%)	0
Initial 3 ranibizumab injections, 𝑛 (%)
No
1	11 (2.3%)	3 (0.8%)
2	25 (5.3%)	15 (4.1%)
Yes	435 (92.4%)	352 (95.1%)
Total number of ranibizumab injections	(≤12 months)	(12 months)
Mean±SD	4.4±1.6	4.7±1.6
Range	0–10	1–10
Number of visits	(≤12 months)	(12 months)
Mean±SD	9.4±2.6	10.3±1.8
Range	1–14	5–14
Discontinuation before month 12, 𝑛 (%)	101 (21.4%)
Reason for discontinuation, 𝑛 (%)
Withdrawal of informed consent	2 (0.4%)	—
Decline further injections	6 (1.2%)	—
Serious complication	1 (0.2%)	—
Retinal detachment	0	—
Referred for continuous follow up	7 (1.5%)	—
Physician’s decision that no further	34 (7.2%)	—
followup is necessary
Other reason	43 (9.1%)	—
Unknown	8 (1.7%)	—